sparingvision.com

Our company

We are a biotechnology company focused on the discovery and development of genomic medicines for the treatment of blinding inherited retinal diseases.
Our goal

Bringing innovative treatments to physicians and patients to address serious ocular disorders.
Press release

Friday, 19 March 2021 07:00

SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

SparingVision Raises €44.5 Million

About SPVN06

SPVN06 is a breakthrough treatment for retinitis pigmentosa, an orphan inherited retinal disease which leads to blindness and affects nearly two million people worldwide.

Retinitis pigmentosa

A group of inherited retinal diseases which are a leading cause of blindness globally.
Scientific Discovery

Over the last 20 years, the scientific founders of SparingVision have, with the support of other world leaders in the space, identified the relation between the survival of rods and the protection of cones, the latter being essential to preserve vision in retinitis pigmentosa patients.
Genomic Medicine

Our lead product, SPVN06, is a gene therapy for the two synergetic isoforms of the NXNL1 gene (RdCVF and RdCVFL) into a single vector to treat patients who are experiencing degeneration of rods and partial vision loss.

SPVN06

Our lead product, SPVN06 is a breakthrough therapy for retinitis pigmentosa (RP), an orphan inherited retinal disease which leads to blindness and affects nearly two million individuals worldwide....